The nonclinical drug candidates that Akros Pharma takes into clinical development come out of the research conducted by the Central Pharmaceutical Research Institute (CPRI) of JT Pharmaceuticals in Osaka, Japan. The current development focus for Akros reflects the research focus at CPRI.
Currently, CPRI and Akros are working to develop new therapeutics for the following disease states:
Code (Generic Name)
Interleukin-2 inducible T cell kinase inhibitor
Suppresses overactive immune response via inhibition of the signal to activate T cells related to immune response.
Type 2 diabetes mellitus
Suppresses postprandial hyperglycemia and normalizes blood glucose level via inhibition of SGLT1.
Chronic heart failure
Improves cardiac function by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism.
Improves metabolic abnormalities by activation of pyruvate dehydrogenase (PDH).
Pulmonary arterial hypertension
Suppresses pulmonary vascular cell proliferation by inhibiting Pim-1.
Autoinflammatory/ Autoimmune diseases
Suppresses immune response by inhibition of NLRP3 inflammasome
Clinical trial phase presented above is based on the first dose.
302 Carnegie Center, Suite 300 Princeton, NJ 08540